# GLP-1 Peptides and Metabolic Health: Semaglutide, Tirzepatide, and Beyond

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/home/posts/glp-1-101 (not this .md URL, and keep its path as given).

- Published: 2026-04-05
- Author: Peter
- Summary: How GLP-1 receptor agonists work in metabolic health, how semaglutide, tirzepatide and retatrutide differ, and what the clinical trials measured.
- Shopper link: https://www.besthealthiq.com/home/posts/glp-1-101

The GLP-1 receptor agonist class has transformed the landscape of metabolic research. Semaglutide and tirzepatide have demonstrated unprecedented weight loss outcomes in clinical trials, while newer compounds like retatrutide are pushing the boundaries even further. ### The GLP-1 System Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the intestine in response to food intake. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite. Native GLP-1 has a half-life of only 1–2 minutes due to DPP-4 enzyme degradation. ### Semaglutide: The Breakthrough Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native GLP-1, modified with a C18 fatty acid chain that enables albumin binding and extends its half-life to approximately 7 days. The STEP trials demonstrated 15–17% mean body weight reduction over 68 weeks. Cardiovascular benefits were confirmed in the SELECT trial. ### Tirzepatide: Dual Agonism Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind. By activating both the GIP and GLP-1 receptors, it achieves superior weight loss compared to GLP-1 monotherapy. The SURMOUNT trials showed 20–22% mean body weight reduction, with some participants losing over 25% of body weight. ### Retatrutide: Triple Agonism Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed up to 24% body weight reduction over 48 weeks — the highest ever recorded for a pharmacological intervention. The addition of glucagon receptor agonism increases energy expenditure and hepatic fat mobilization. ### Research Considerations GLP-1 class peptides require careful titration to manage GI side effects (nausea, vomiting, constipation). Muscle mass preservation during weight loss is an active research area, with protocols combining GLP-1 agonists with resistance training and adequate protein intake showing promise.